Kunshi Biological: Trepelumab has been approved for first-line treatment of melanoma in China.

On April 25th, Junshi Biosciences announced that the new indication for its independently developed anti-PD-1 monoclonal antibody injection, Toripalimab, for the first-line treatment of unresectable or metastatic melanoma, has recently been approved by the National Medical Products Administration. This is the 12th indication for Toripalimab approved in mainland China.